What are the key takeaways from this The Readout Loud episode?

Key insights include: **Neuroplasticity mechanism:** Psychedelics activate serotonin receptors to promote rapid structural brain rewiring in the prefrontal cortex, which atrophies in depression and PTSD. This physical repair produces therapeutic effects within 24 hours versus weeks with SSRIs, and benefits persist long after drug clearance. Every effective antidepressant intervention promotes cortical neuron growth, making neuroplasticity central to treating neuropsychiatric conditions.; **Dose-dependent efficacy:** Zalzupendol demonstrates concentration-dependent therapeutic effects—higher doses produce stronger antidepressant responses without causing hallucinations. Over 100 patients have taken the drug with only mild nausea and headaches at very high doses. The compound shows identical EEG biomarkers for neuroplasticity as ketamine and psychedelics, confirming brain engagement despite lacking hallucinogenic properties.; **Episodic dosing paradigm:** Phase one trials tested two regimens—daily dosing for seven days versus two doses on days one and four—both producing identical rapid MADRS score reductions sustained four weeks post-treatment. This episodic approach mirrors electroconvulsive therapy protocols and treats depression as an episodic disease, eliminating need for daily medication and allowing retreatment only when episodes recur.

What did David Olson discuss on The Readout Loud?

Tracy Beth Hoag becomes FDA's new drug center leader after Rick Pazder's departure over concerns about commissioner Marty Makari's influence. David Olson discusses developing neuroplastogens—drugs that provide psychedelic therapeutic benefits without hallucinogenic effects—and Delix Therapeutics' phase one trial results showing rapid antidepressant effects comparable to traditional psychedelics. Key topics include: **Neuroplasticity mechanism:** Psychedelics activate serotonin receptors to promote rapid structural brain rewiring in the prefrontal cortex, which atrophies in depression and PTSD. This physical repair produces therapeutic effects within 24 hours versus weeks with SSRIs, and benefits persist long after drug clearance. Every effective antidepressant intervention promotes cortical neuron growth, making neuroplasticity central to treating neuropsychiatric conditions.; **Dose-dependent efficacy:** Zalzupendol demonstrates concentration-dependent therapeutic effects—higher doses produce stronger antidepressant responses without causing hallucinations. Over 100 patients have taken the drug with only mild nausea and headaches at very high doses. The compound shows identical EEG biomarkers for neuroplasticity as ketamine and psychedelics, confirming brain engagement despite lacking hallucinogenic properties..

How long is this episode of The Readout Loud?

This episode is 32 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Readout Loud

380: A new top drug regulator and the future of psychedelics

December 4, 2025

32 min episode · 2 min read

David Olson

Episode

32 min

Read time

2 min

Topics

Productivity, Sales & Revenue, Psychology & Behavior

AI-Generated Summary

Published Feb 12, 2026

Key Takeaways

✓Neuroplasticity mechanism: Psychedelics activate serotonin receptors to promote rapid structural brain rewiring in the prefrontal cortex, which atrophies in depression and PTSD. This physical repair produces therapeutic effects within 24 hours versus weeks with SSRIs, and benefits persist long after drug clearance. Every effective antidepressant intervention promotes cortical neuron growth, making neuroplasticity central to treating neuropsychiatric conditions.
✓Dose-dependent efficacy: Zalzupendol demonstrates concentration-dependent therapeutic effects—higher doses produce stronger antidepressant responses without causing hallucinations. Over 100 patients have taken the drug with only mild nausea and headaches at very high doses. The compound shows identical EEG biomarkers for neuroplasticity as ketamine and psychedelics, confirming brain engagement despite lacking hallucinogenic properties.
✓Episodic dosing paradigm: Phase one trials tested two regimens—daily dosing for seven days versus two doses on days one and four—both producing identical rapid MADRS score reductions sustained four weeks post-treatment. This episodic approach mirrors electroconvulsive therapy protocols and treats depression as an episodic disease, eliminating need for daily medication and allowing retreatment only when episodes recur.
✓First-line treatment positioning: Non-hallucinogenic neuroplastogens can serve as first-switch treatments after generic SSRIs fail, rather than reserving them for treatment-resistant patients like traditional psychedelics. FDA approval for at-home dosing in phase two trials enables broader patient access without clinic supervision requirements. Patients can determine treatment response within days instead of cycling through months of failed medication trials.
✓Regulatory consolidation concerns: Rick Pazder resigned as FDA drug center leader after one month due to concerns about commissioner Makari handpicking hires, inserting himself into drug review decisions, and promoting a commissioner voucher program for expedited reviews. Tracy Beth Hoag, who challenged COVID policies during the pandemic, replaces him, consolidating power among officials aligned with RFK Jr and Vinay Prasad's vaccine skepticism.

What It Covers

Tracy Beth Hoag becomes FDA's new drug center leader after Rick Pazder's departure over concerns about commissioner Marty Makari's influence. David Olson discusses developing neuroplastogens—drugs that provide psychedelic therapeutic benefits without hallucinogenic effects—and Delix Therapeutics' phase one trial results showing rapid antidepressant effects comparable to traditional psychedelics.

Key Questions Answered

•Neuroplasticity mechanism: Psychedelics activate serotonin receptors to promote rapid structural brain rewiring in the prefrontal cortex, which atrophies in depression and PTSD. This physical repair produces therapeutic effects within 24 hours versus weeks with SSRIs, and benefits persist long after drug clearance. Every effective antidepressant intervention promotes cortical neuron growth, making neuroplasticity central to treating neuropsychiatric conditions.
•Dose-dependent efficacy: Zalzupendol demonstrates concentration-dependent therapeutic effects—higher doses produce stronger antidepressant responses without causing hallucinations. Over 100 patients have taken the drug with only mild nausea and headaches at very high doses. The compound shows identical EEG biomarkers for neuroplasticity as ketamine and psychedelics, confirming brain engagement despite lacking hallucinogenic properties.
•Episodic dosing paradigm: Phase one trials tested two regimens—daily dosing for seven days versus two doses on days one and four—both producing identical rapid MADRS score reductions sustained four weeks post-treatment. This episodic approach mirrors electroconvulsive therapy protocols and treats depression as an episodic disease, eliminating need for daily medication and allowing retreatment only when episodes recur.
•First-line treatment positioning: Non-hallucinogenic neuroplastogens can serve as first-switch treatments after generic SSRIs fail, rather than reserving them for treatment-resistant patients like traditional psychedelics. FDA approval for at-home dosing in phase two trials enables broader patient access without clinic supervision requirements. Patients can determine treatment response within days instead of cycling through months of failed medication trials.
•Regulatory consolidation concerns: Rick Pazder resigned as FDA drug center leader after one month due to concerns about commissioner Makari handpicking hires, inserting himself into drug review decisions, and promoting a commissioner voucher program for expedited reviews. Tracy Beth Hoag, who challenged COVID policies during the pandemic, replaces him, consolidating power among officials aligned with RFK Jr and Vinay Prasad's vaccine skepticism.

Notable Moment

Retro Bio, the longevity startup backed by Sam Altman, seeks a $5 billion valuation before starting its first clinical trial or generating any patient data. Internal pitch decks project the company's market cap could surpass Eli Lilly and Novo Nordisk, approaching valuations of tech giants like Alphabet and Microsoft by combining longevity research with AI drug development applications.

Know someone who'd find this useful?

Episode Transcript

Welcome to this week's episode of The Read Out Loud, a weekly biotech podcast from STAT. I'm Allison DeAngelis. I'm Adam Feuerstein. And I'm Elaine Chen. It's Thursday, December 4, and here's what we're gonna talk about this week. There's a growing interest in psychedelics from pharma investors and regulators. And with that, there's also growing debate about whether the psychedelic aspect of these drugs is actually needed to help treat depression, anxiety, and other psychiatric conditions. David Olson, a longtime psychedelics researcher, has psychedelics researcher, has cofounded a company focused on developing psychedelics without the hallucinogenic trip. He joins us this week to discuss. But first, a word from our sponsor and a roundup of this week's biotech news. Hey, Read Out Loud listeners. Bob Herman here, stats business of health care reporter and the writer behind the newsletter, HealthCare Inc. HealthCare Inc is a weekly newsletter devoted to unpacking the business and secret inner workings of The US health care industry. If you're someone who has ever received a medical bill or craves in-depth policy explainers or loves a playful meme now and again, I highly recommend you check this newsletter out. Learn more at the link in this episode's description. And now back to our regularly scheduled programming. Thanks. So you may have heard Adam there in the introduction, but it's just us in the studio right now, Elaine. Right? Yeah. It's just you and me right now. We had recorded our interview that's gonna come later in this episode with Adam a day earlier because Adam is now headed out to the American Society of Hematology conference. But overnight news broke, so here we are, you and me, Allison, talking about the news. I do have to say I did jinx it because yesterday, I said, oh, I hope there's not big news that comes overnight. It's okay. Elaine, I'm not gonna hold that against you. And you know what the show must go on? Yes. So the big news we're talking about is Tracy Beth Hoag becoming the next leader of the FDA's drug center, CDER. She'll replace Rick Pazder, who is leaving the FDA just less than a month after he agreed to take on this role of leading CDER. Yeah. Sources told stat that Pazder was concerned about the legality of a new commissioner voucher program that offers expedited review to drugs that align with national priorities. He also took issue with commissioner Marty Makari and top biologics regulatory official Vinay Prasad inserting themselves into drug review decisions as well as efforts by Makari to handpick hires for the drug center. Yeah. And as for Hogue, she's a sports medicine physician and epidemiologist who rose to prominence during the pandemic because she was challenging school closures, mass mandates, and the approval of booster shots for children. This comes soon after Vinay Prasad had sent out a memo to staff claiming that the COVID nineteen vaccine was responsible for the deaths of ten children, …

Get the full transcript (5,108 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Readout Loud transcripts →